Safety and immunogenicity of an Escherichia coli-produced bivalent human papillomavirus type 6/11 vaccine: A dose-escalation, randomized, double-blind, placebo-controlled phase 1 trial

• Main Authors: Zhao-Jun Mo (Author), Zhao-Feng Bi (Author), Wei Sheng (Author), Qi Chen (Author), Teng Huang (Author), Ming-Qiang Li (Author), Xue-Lian Cui (Author), Ya-Hui Wangjiang (Author), Bi-Zhen Lin (Author), Feng-Zhu Zheng (Author), Guang Sun (Author), Ya-Fei Li (Author), Ya Zheng (Author), Si-Jie Zhuang (Author), Ying-Ying Su (Author), Hui-Rong Pan (Author), Shou-Jie Huang (Author), Ting Wu (Author), Jun Zhang (Author), Ning-Shao Xia (Author)
• Format: Book
• Published: Taylor & Francis Group, 2022-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

A dose-escalation, randomized, double-blind, placebo-controlled phase 1 clinical trial enrolled 145 eligible participants aged 18-55 years in March 2015 in Liuzhou, China. Stratified by age and sex, the participants were randomly assigned to receive either 30, 60, or 90 μg of the HPV-6/11 vaccine (n...